FOOD AND DRUG ADMINISTRATION

Center for Drug Evaluation and Research

Endocrinologic and Metabolic Drugs Advisory Committee Meeting

FDA White Oak Campus, Building 31, the Great Room, White Oak Conference Center (Room 1503), 10903 New Hampshire Avenue, Silver Spring, MD
October 16, 2013

MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (NON-VOTING)

Stephanie L. Begansky, PharmD

Division of Advisory Committee and Consultant Management Office of Executive Programs Center for Drug Evaluation and Research

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS (VOTING)

Erica H. Brittain, PhD

Mathematical Statistician
Biostatistics Research Branch
National Institute of Allergy and Infectious
Diseases (NIAID)
National Institutes of Health (NIH)
Bethesda, Maryland

David W. Cooke, MD

Clinical Director, Division of Pediatric Endocrinology Director, Pediatric Endocrine Fellowship Training Program Johns Hopkins University School of Medicine Baltimore, Maryland

Edward W. Gregg. Ph.D.

Chief, Epidemiology and Statistics Branch Division of Diabetes Translation Centers for Disease Control and Prevention Atlanta, Georgia

Diana Hallare, MPH

(Consumer Representative)
Visalia, California

William R. Hiatt, MD, FACP

Professor of Medicine Division of Cardiology University of Colorado School of Medicine President, Colorado Prevention Center (CPC) Clinical Research Aurora, Colorado

Ellen W. Seelv, MD

Professor of Medicine Harvard Medical School Division of Endocrinology, Diabetes and Hypertension Brigham and Women's Hospital Boston, Massachusetts

Robert J. Smith, MD

(Acting Chairperson)

Professor of Medicine (Endocrinology)
Alpert Medical School of Brown University
Ocean State Research Institute
Providence Veterans Administration Medical
Center
Providence, Rhode Island

FOOD AND DRUG ADMINISTRATION

Center for Drug Evaluation and Research

Endocrinologic and Metabolic Drugs Advisory Committee Meeting

October 16, 2013

MEETING ROSTER (cont.)

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE **MEMBERS (NON-VOTING)**

Mads F. Rasmussen, MD, PhD

(Industry Representative)

Executive Director

Clinical Development and Research, Diabetes

Clinical Development

Medical and Regulatory Affairs

Novo Nordisk Inc.

Princeton, New Jersey

TEMPORARY MEMBERS (VOTING)

Brendan M. Everett, MD, MPH

Assistant Professor

Harvard Medical School

Director General Cardiology Inpatient

Service

Cardiovascular and Preventive Medicine

Brigham and Women's Hospital

Boston, Massachusetts

Frank Harrell, PhD

Professor of Biostatistics

Chair, Department of Biostatistics

Vanderbilt University School of Medicine

Nashville, Tennessee

Pamela McAllister, PhD

(Patient Representative)

Research Advocate, Fight Colorectal Cancer

Alexandria, Virginia

Peter W.F. Wilson, MD

Professor of Medicine

Emory University

School of Medicine

Department of Cardiology

Atlanta, Georgia

FDA PARTICIPANTS (Non-Voting)

Mary H. Parks, MD

Deputy Director

Office of Drug Evaluation II (ODE-II)

Office of New Drugs (OND), CDER, FDA

Jean-Marc Guettier, MD

Director (Acting)

Division of Metabolism and Endocrinology Products (DMEP), ODE-II, OND, CDER,

FDA

Eric Colman, MD

Deputy Director

DMEP, ODE-II, OND, CDER, FDA

James P. Smith, MD, MS

Clinical Team Leader

DMEP, ODE-II, OND, CDER, FDA

Mary Dunne Roberts, MD

Clinical Reviewer

DMEP, ODE-II, OND, CDER, FDA